See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Diabetes Medications

Updated 5 days ago
Diabetes Health: Research for the Cure Puzzle #21
Sep 21, 2014 | 
Test your knowledge to see how well you know research for the cure.
Diabetes Patients On Metformin Show Better Lipid Profile
Sep 10, 2014 | 
Chinese researchers found that type 2 diabetes patients taking metformin – one of the first lines of defense in the treatment of the disease - attained a better overall lipid profile compared with those who took glipizide.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

Todd speaks about Levemir

Todd Hobbs

Todd speaks about Levemir

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

New Dual Artificial Pump- Still in Development
Sep 5, 2014 | 
Tandem is in partnership with the JDRF to develop a dual hormone pump which will continue to be funded, as Tandem reaches different milestones. Once approved by the FDA, this novel and groundbreaking medical device will have two hormone chambers. One chamber for insulin, the second chamber for a different hormone that supports different therapies. “At this time, insulin is the only approved hormone for an insulin pump,” says Susan Morrison, Chief Administrative Officer from Tandem Diabetes Care.
Diabetes Health: What You Need for Injections Crossword Puzzle Solution for #18
Sep 1, 2014 | 
If you would like to sign up to receive a weekly puzzle, please email puzzle@diabeteshealth.com. In the subject area write "add me to your weekly word puzzle list." If you would like us to create a puzzle for you and our players, send your 8 words to puzzle@diabeteshealth.com and we will post your challenge online. In the subject area write, "create my special puzzle". We can all have fun posting and solving your crossword puzzle.
Diabetes Health: What You Need for Injections Crossword Puzzle #18
Aug 31, 2014 | 
Test your knowledge to see how well you understand what you need for injections.
Dompé Earns Orphan Drug
Aug 20, 2014 | 
An Italian-based pharmaceutical company with subsidiaries in New York has been granted orphan drug status for a new drug to treat neurotrophic keratitis, a rare degenerative corneal disease that impacts less than 1 in 5,000 people worldwide.
FDA Lifts Restrictions on Patient Access to Avandia
Aug 7, 2014 | 
The type 2-diabetes drug Avandia will again be available through retail pharmacies after a May ruling by the U.S. Food and Drug Administration.

The drug - a rosiglitazone-based medicine that controls blood glucose by increasing the body’s sensitivity to insulin, so cells and muscles are able to use more for energy, reducing levels in the blood - was off the market in Europe and restricted in the United States for several years due to studies showing the drug raised the risk of heart disease. The FDA in 2013 reversed its earlier opinion and lifted restrictions on the drug, opening the doors for Avandia’s return to market.

Initially released in 1999, Avandia had been one of Glaxo's top-selling medicines, with sales of $3.2 billion in 2006. Sales tanked in 2010 after a review of clinical trials showed an increased risk of heart attack related to the drug – those taking the drug in the United States dropped from 120,000 to 3,000 – but last year, new trials showed no elevated risk of heart attack or death in patients being treated with Avandia compared to other diabetes drugs, causing the FDA to reverse its opinion.

“GSK welcomes the decision of the FDA and appreciates the agency’s robust review of the science about Avandia,” Glaxo said in a statement last year. “GSK maintains its view that Avandia is a safe and effective treatment for Type 2 diabetes when used appropriately.”

While the drug had previously been available only through specialty pharmacies and the patients already taking the drug or whose symptoms were not adequately controlled by other drugs, the new FDA ruling allows all patient's access to Avandia, Avandamet and Avandaryl. All of these medications contain rosiglitazone.

“Our actions reflect the most current scientific knowledge about the risks and benefits of this drug,” Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in a statement last year. “Given these new results, our level of concern is considerably reduced; thus, we require the removal of certain prescribing restrictions.”

While the drug’s manufacturer, GlaxoSmithKline, has a marketing hurdle to overcome given the bad press the drug has received over the last few years, the British drug maker has no plans to promote Avandia in the United States, in part because its U.S. patent protection lapsed in 2011.
The drug will be available by prescription.

To assist in the transition, a toll-free telephone number has been established for patients, healthcare professionals and pharmacies - 1-800-282-6342 – which will be staffed from 8;30 a.m. to 5 p.m. Monday through Friday Eastern Time.
Next Page »  
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.